BEIJING, Jan. 24, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: ), a leading provider of vaccines in China, today announced that it received a letter dated January 18, 2012 from The Nasdaq Stock Market. Based on the departure of Ms. Chup Hung Mok from the Company's Board of Directors effective January 4, 2012, Nasdaq has determined that the Company no longer complies with Nasdaq's requirement that its audit committee consists of at least three independent directors, as set forth in Listing Rule 5605. However, consistent with Listing Rule 5605(c)(4), Nasdaq will provide the Company a cure period in order to regain compliance of until the earlier of the Company's next annual shareholders meeting or January 4, 2013; or if the next annual shareholders' meeting is held before July 2, 2012, then the Company must evidence compliance no later than July 2, 2012.
As announced on January 4, 2012, the Board has an active search ongoing to locate a suitable replacement for Ms. Mok. The Company intends to submit to Nasdaq documentation, including biographies of any new directors, evidencing compliance with the rules no later than this date.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical
company that focuses on the research, development,
manufacture and commercialization of vaccines that protect
against human infectious diseases including hepatitis A,
seasonal influenza, H5N1 (bird flu) pandemic influenza and
H1N1 influenza. In 2009, Sinovac was the first company
worldwide to receive approval for its H1N1 influenza
vaccine, PANFLU.1, and has received orders from the Chinese
Central Government pursuit to the government stockpiling
program. The Company is developing a number of new vaccine
products, including vaccines for pneumococcal conjugate,
enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease),
pneumococcal polysaccharides, human rabies, HIB, rotavirus
and epidemic meningitis, chickenpox and mumps & rubella.
Its wholly owned subsidiary, Tangshan Yian, is focusing on
the research, development, manufacturing and
commercialization of animal vaccines, and has launched its
internally developed inactivated rabies vaccine in China.
Safe Harbor Statement
This announcement contains forward-looking statements.
These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will,"
"expects," "anticipates,"
"future," "intends," "plans,"
"believes," "estimates" and similar
statements. Among other things, the business outlook and
quotations from management in this press release contain
forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties. A number of important factors could cause
actual results to differ materially from those contained in
any forward-looking statement. Sinovac does not undertake
any obligation to update any forward-looking statement,
except as required under applicable law.
distribué par | Ce noodl a été diffusé par Sinovac Biotech Ltd. et initialement mise en ligne sur le site http://www.sinovac.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-25 07:37:53 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |